Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02068027 · ClinicalTrials.gov registry record · Phase 2
Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy
A Phase 2 study, sponsored by BioDelivery Sciences International.
- Completed
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
NCT02068027 is a Phase 2 study that has completed, run by BioDelivery Sciences International. The registered enrollment target is 260 participants.
The verdict
NCT02068027, a Phase 2 study, has completed, sponsored by BioDelivery Sciences International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether clonidine gel is an effective treatment for reducing the pain associated with painful diabetic neuropathy.
Interventions
- DRUG Placebo
- DRUG Clonidine Gel 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02068027
The ClinicalTrials.gov registry entry for NCT02068027 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioDelivery Sciences International, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02068027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02068027 about?
NCT02068027 is a clinical study titled "Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy". The purpose of the study is to determine whether clonidine gel is an effective treatment for reducing the pain associated with painful diabetic neuropathy.
What is the current status of trial NCT02068027?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2014-03. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02068027?
The interventions under investigation include: Placebo (DRUG), Clonidine Gel 0.1% (DRUG).
Who is sponsoring clinical trial NCT02068027?
This trial is sponsored by BioDelivery Sciences International, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.